Scientific understanding of genetic irregularities and associated diseases is increasing at a robust rate, resulting in the emergence of the long-awaited era of precision medicine.
The growing adoption of high-throughput biological screening processes, such as next-generation sequencing (NGS), can offer vital insights for pharmacogenomic-related drug development, starting from patient stratification and clinical profiling to biomarker discovery and target evaluation in the pharmaceutical industry.
This is motivating pharmaceutical companies to learn about the effectiveness of precision treatments in patient sub-populations using innovative real-world data (RWD) solutions, such as electronic medical records (EMRs).
Opening the Aperture in Precision Medicine
At the moment, the fields of medicine and health care are abuzz with interest in the emerging field of precision medicine. With the ability to provide effective, tailored therapeutic strategies based on an individual's epigenomics, genomics,
and proteomics, precision medicine has the potential to revolutionize medical interventions.
The field not only has the capability to transform several medical treatments but also to transform diagnostics and prevention solutions. Increasing molecular stratification of patients, such as testing for mutations that lead to resistance to certain therapies, is providing medical professionals with solid evidence encouraging them to opt for precision medicine treatments.
necessitates a thorough understanding of a disease's natural history, specifically the genes and gene variants involved and their correlation to patient phenotypes, making it particularly effective for the treatment of types of cancers
With the rising emphasis on the use of genomics and clinical data to deeply understand the interplay of phenotype and genotype in health and disease, pharmaceutical organizations are increasingly investing in the precision medicine field.
The Road to the Future
Precision medicine is providing a huge opportunity to shape the future of the pharmaceutical and healthcare industries. While the field is currently the most advanced in oncology, it has broader, finding applications beyond oncology and late-stage disease, such as in genetic and rare diseases.
Also, many pharmaceutical businesses have shifted their vision from, 'one-drug-treats-all' to the 'right drug, right patient, right time,' approach, especially in the domains of oncology and neuroscience. They are also investing in the field to acquire a deeper understanding and find novel applications of precision medicine. This is anticipated to increase the adoption of precision medicine in the pharmaceutical industry.